Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-02-15
2011-02-15
Shameem, Golam M (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S146000, C548S190000, C548S194000, C544S106000, C544S111000, C544S132000, C514S365000, C514S231500, C514S235500, C546S184000, C546S192000, C546S209000
Reexamination Certificate
active
07888379
ABSTRACT:
The present invention is related to thiazole derivatives of Formula (I) in particular for the treatment and/or prophylaxis of autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, bacterial or viral infections, kidney diseases, platelet aggregation, cancer, transplantation, graft rejection or lung injuries.
REFERENCES:
patent: 6586423 (2003-07-01), Bilodeau et al.
patent: 6586424 (2003-07-01), Bilodeau et al.
patent: 7163952 (2007-01-01), Inaba et al.
patent: 2003/0158199 (2003-08-01), Stieber et al.
patent: 2008/0188531 (2008-08-01), Quattropani et al.
patent: 2008/0221180 (2008-09-01), Quattropani et al.
patent: 2009/0029997 (2009-01-01), Quattropani et al.
patent: 0 117 082 (1984-08-01), None
patent: WO 00/75120 (2000-12-01), None
patent: WO 01/17995 (2001-03-01), None
patent: WO 03/072557 (2003-09-01), None
patent: WO 2004/033439 (2004-04-01), None
patent: WO 2004/052286 (2004-06-01), None
patent: WO 2004/078754 (2004-09-01), None
patent: WO 2004/096797 (2004-11-01), None
patent: WO 2005/021519 (2005-03-01), None
patent: WO 2005/047273 (2005-05-01), None
patent: WO 2005/068444 (2005-07-01), None
patent: WO 2006/051270 (2006-05-01), None
Bilodeau et al (2001): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2001:185751.
Bold et al (2005): STN International HCAPLUS database, (Columbus, Ohio), Accession No. 2005:451371.
Beaton, C. M. et al. “Some Derivatives of 2- and 3-Phenylthiophen”J. Chem. Soc., 1976, pp. 2355-2563, vol. I.
Bellina, F. et al. “Palladium Catalysts for the Suzuki Cross-Coupling Reaction: An Overview of Recent Advances”Synthesis, 2004, pp. 2419-2440, No. 15.
Brummond, K. M. et al. “Solid-Phase Synthesis of BRL 49653”J. Org. Chem., 1999, pp. 1723-1726, vol. 64.
Cantley, L.C. “The Phosphoinositide 3-Kinase Pathway”Science, May 31, 2002, pp. 1655-1657, vol. 296.
Fraser, J. D. et al. “Regulation of Interleukin-2 Gene Enhancer Activity by the T Cell Accessory Molecule CD28”Science, Jan. 18, 1991, pp. 313-316, vol. 251.
Fruman, D.A. et al. “Phosphoinositide Kinases”Annu. Rev. Biochem., 1998, pp. 481-507, vol. 67.
Gerard, C. et al. “Chemokines and disease”Nature Immunology, Feb. 2001, pp. 108-115, vol. 2, No. 2.
Grant, S. “Targeted Therapies in Cancer—Second International Congress”Current Drugs, 2003, pp. 946-948, vol. 6, No. 10.
Hirsch, E. et al. “Central Role for G Protein-Coupled Phosphoinositide 3-Kinase γ in Inflammation”Science, Feb. 11, 2000, pp. 1049-1053, vol. 287.
Hirsch, E. et al. “Resistance to thromboembolism in PI3 Kγ-deficient mice”FASEB J., 2001, pp. 2019-2021, vol. 15, No. 11.
Kodomari, M. et al. “One-pot synthesis of 2-aminothiazoles using supported reagents”Tetrahedron Letters, 2002, pp. 1717-1720, vol. 43.
Laffargue, M. et al. “Phosphoninositide 3-Kinase γ Is an Essential Amplifier of Mast Cell Function”Immunity, Mar. 2002, pp. 441-451, vol. 16.
Lawlor, M. A. et al. “PKB/Akt: a key mediator of cell proliferation, survival and insulin responses?”Journal of Cell Science, 2001, pp. 2903-2910, vol. 114.
Parker, P. J. “PI 3-kinase puts GTP on the Rac”Current Biology, 1995, pp. 577-599, vol. 5, No. 6.
Stein, R. C. et al. “PI3-kinase inhibition: a target for drug development?”Molecular Medicine Today, Sep. 2000, pp. 347-357, vol. 6.
Thelen, M. et al. “Wortmannin binds specifically to 1-phosphatidylinositol 3-kinase while inhibiting guanine nucleotide-binding protein-coupled receptor signaling in neutrophil leukocytes”Proc. Natl. Acad. Sci. USA, May 1994, pp. 4960-4964, vol. 91.
Toker, a. “Phosphoinositides and signal transduction”Cellular and Molecular Life Sciences, 2002, pp. 761-779, vol. 59.
Vanhaesebroeck, B. et al. “Phosphoinositide 3-kinases: a conserved family of signal transducers”Trends Biochem. Science, Jul. 1997, pp. 267-272, vol. 22.
Vanhaesebroeck, B. et al. “Synthesis and Function of 3-Phosphorylated Inositol Lipids”Ann. Rev. Biochem., 2001, pp. 535-602, vol. 70.
Wymann, M. P. et al. “Lipids on the move: phosphoinositide 3-kinases in leukocyte function”Immunology Today, Jun. 2000, pp. 260-264, vol. 21, No. 6.
Yao, R. et al. “Requirement for Phosphatidylinositol-3 Kinase in the Prevention of Apoptosis by Nerve Growth Factor”Science, Mar. 31, 1995, pp. 2003-2005, vol. 267.
Guarna, A. et al. “Synthesis and Reactivity of Bicycles Derived from Tartaric Acid and α-Amino Acids: A Novel Class of Conformationally Constrained Dipeptide Isosteres Based upon Enantiopure 3-Aza-6, 8-dioxabicyclo [3.2.1] octane-7-carboxylic Acid”J. Org. Chem., 1999, pp. 7347-7364, vol. 64.
Herr, R. J. et al. “A Convenient Method for the Preparation of Primary and SymmetricalN,N′- Disubstituted Thioureas”Synthesis, 2000, pp. 1569-1574, No. 11.
Pirrung, M.C. et al. “Trityl Isothiocyanate Support for Solid-Phase Synthesis”J. Comb. Chem., 2001, pp. 90-96, vol. 3.
Sawhney, S. N. et al. “Thiazole Derivatives: Part I—Synthesis & Anti-Inflammatory Activity of some 2′-Alkyl/Aryl-2-Aryl-4-Methyl-4′5-Bithiazolyls & 2′Amino-Substituted Amino-2-Aryl-4-Methyl-4′5-Bithiazolyls”Indian Journal of Chemistry, Jul. 1976, pp. 552-555, vol. 14B, No. 7.
Sayed, S.M. et al. “Synthesis and Reactivity of Cyanomethyl 2-Amino-4-methylthiazolyl Ketone. A Facile Synthesis of Novel Pyrazolo [5,1-c] 1,2,4-triazine, 1,2,4-Triazolo [5,1-c] 1, 2,4,-triazine, 1,2,4-Triazino [4,3-a] benzimidazole, Pyridazine-6-imine and 6-Oxopyridazinone Derivatives”Heteroatom Chemistry, 1999, pp. 385-390, vol. 10, No. 5.
Wilson, K.J. et al. “Synthesis of Thiophene-2-carboxamidines Containing 2-Amino-thiazoles and their Biological Evaluation as Urokinase Inhibitors”Bioorganic&Medicinal Chemistry Letters, 2001, pp. 915-918, vol. 11.
Wittenberger, S.J. et al. “Dialkyltin Oxide Mediated Addition of Trimethylsilyl Azide to Nitriles. A Novel Preparation of 5-Substituted Tetrazoles”J.Org. Chem., 1993, pp. 4139-4141, vol. 58.
Inaba, T. et al., 2002, CAS: 136:177998, pp. 1-4.
Office Action dated Apr. 6, 2010 in U.S. Appl. No. 11/915,521, filed Nov. 26, 2007.
Office Action dated Nov. 24, 2009 in U.S. Appl. No. 11/915,476, filed Nov. 26, 2007.
Allowed claims in U.S. Appl. No. 11/915,476, filed Nov. 26, 2007.
Pending claims in U.S. Appl. No. 11/915,521, filed Nov. 26, 2007.
Pending claims in U.S. Appl. No. 12/159,663, filed Jun. 30, 2008.
Covini David
Dorbais Jerome
Pomel Vincent
Quattropani Anna
Rueckle Thomas
Merck Serono SA
Saliwanchik Lloyd & Eisenschenk
Shameem Golam M
LandOfFree
Thiazole derivatives and use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazole derivatives and use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazole derivatives and use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2640926